StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
UBS on Danaher (DHR): 'we believe the CPHD platform will continue to see traction as COVID-19 becomes endemic'
July 21, 2022 11:24 AM
UBS analyst Elizabeth Garcia reiterated a Buy rating and $297.00 price target on Danaher (NYSE: DHR).The analyst comments "DHR kicked ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Next Articles
KeyBanc Remains Positive on Life Sciences as 'Strong' Earning Season Begins with Danaher (DHR) Report
July 21, 2022 11:40 AM
Cowen Reiterates Outperform Rating on Danaher (DHR), 'We expect the stock to react favorably'
July 21, 2022 10:22 AM
Stifel Reiterates Hold Rating on Danaher (DHR), 'we are impressed with the company's ability to perform'
July 21, 2022 10:21 AM
Thermo Fisher Scientific (TMO), Other Danaher (DHR) Peers Surge
July 21, 2022 10:18 AM
Danaher (DHR) Tops Q2 EPS by 40c
July 21, 2022 6:03 AM
Danaher Reports Second Quarter 2022 Results
July 21, 2022 6:00 AM
Stocks expected to have increasing option volume: DHR T PM BX KEY DGX
July 21, 2022 5:23 AM
Beckman Coulter and Scopio Labs Partner to Accelerate Adoption of Hematology Digital Cell Morphology Platform
July 20, 2022 8:00 AM
UBS Starts Danaher (DHR) at Buy
July 20, 2022 5:06 AM
Form 4 DANAHER CORP /DE/ For: Jul 15 Filed by: Dewan Feroz
July 19, 2022 5:02 PM
Form 4 DANAHER CORP /DE/ For: Jul 15 Filed by: Couchara Georgeann
July 19, 2022 5:02 PM
